Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 06, 2015 8:40 AM ET

Pharmaceuticals

Company Overview of Blend Therapeutics, Inc.

Company Overview

Blend Therapeutics, Inc. offers drug discovery and development services. It focuses on cancer therapies and drugs development. The company was formerly known as Blend Biosciences, Inc. Blend Therapeutics, Inc. was founded in 2011 and is based in Watertown, Massachusetts.

134 Coolidge Avenue

Watertown, MA 02472

United States

Founded in 2011

Phone:

617-923-4100

Fax:

617-923-4101

Key Executives for Blend Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 47
Founder, Chairman of The Board and Member of Scientific Advisory Board
Age: 45
Founder, Director and Member of Scientific Advisory Board
Age: 66
Founder and Chairman of Scientific Advisory Board
Head of Finance
Compensation as of Fiscal Year 2014.

Blend Therapeutics, Inc. Key Developments

Blend Therapeutics Appoints Drew Fromkin as President and Chief Executive Officer

Blend Therapeutics, Inc. appointed Drew Fromkin as President and Chief Executive Officer and a member of the company’s Board of Directors. Mr. Fromkin previously served as President and Chief Executive Officer of Clinical Data, Inc. He is an accomplished, global healthcare leader with more than 25 years of experience leading private and public life sciences and healthcare services companies through all stages of growth, including product development and commercial operations. Mr. Fromkin takes on the role of CEO at a pivotal time when Blend is positioned to rapidly advance its novel pipeline of innovative anti-cancer therapeutics into human clinical trials in a variety of cancers. He will lead the company in its plans to file two Investigational New Drug (IND) applications with the U.S. Food and Drug Administration, respectively, in second quarter 2015 for its novel personalized cisplatin prodrug, BTP-114, and in early 2016 for its first targeted drug candidate from its proprietary Pentarin™ platform, BTP-277. BTP-114.

Blend Therapeutics, Inc. Appoints Dennis A. Ausiello, MD to Board of Directors

Blend Therapeutics, Inc. announced that it has appointed Dennis A. Ausiello, MD, to the company’s board of directors. As Physician-in-Chief, Emeritus at Massachusetts General Hospital (MGH), Dr. Ausiello. He is currently the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School and Director of the Center for Assessment Technology and Continuous Health (CATCH).

Blend Therapeutics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 02:45 PM

Blend Therapeutics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 02:45 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
Tasty Greenz, LLC United States
Quantum, Inc. United States
Jaguar Animal Health, Inc. United States
US WorldMeds, LLC United States
Virologix Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Blend Therapeutics, Inc., please visit www.blendtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.